A national center of excellence for dementia care and research

The Biggs Institute for Alzheimer’s and Neurodegenerative Diseases at UT Health San Antonio is one of 33 centers in the nation and the only one in Texas recognized as a National Institute on Aging (NIA)- designated Alzheimer’s Disease Research Center.

This designation takes our research and care to the next level as we approach dementia care as a team of experts to provide you all the tests needed for a diagnosis and a comprehensive treatment plan with access to innovative treatments through clinical trials.

From diagnosis to supportive and educational resources, our team is here to provide the dementia care you and your family need.

Learn more about our NIA designation

A new era in Alzheimer’s treatment: FDA approval on lecanemab

The U.S. Food and Drug Administration on Friday, Jan. 6, 2023, approved lecanemab, a drug that targets the basic pathophysiology of Alzheimer’s disease. The FDA action is an “accelerated approval” of the drug, and the FDA requests continued diligent gathering of evidence on effectiveness and safety. A decision about full approval is a few weeks or months away and may be positive or negative. Regardless, the accelerated approval is a hopeful step forward.

Read our statement about the timely topic in dementia treatment